THE INTERNATIONAL MYELOMA REGISTRY (IMR)
The Multiple Myeloma Registry is an important quality assurance tool for implementing and reviewing guidelines and their efficacy in regional, national and multinational patient populations, the assessment of adverse reactions in large patient populations outside a clinical trial and pharmacoeconomic analysis under “real life” conditions.
IMR - High quality patient data
Centers worldwide feed in patient records from myeloma patients.
The Multiple Myeloma Registry is an important quality assurance tool for implementing and reviewing guidelines and their efficacy in regional, national and multinational patient populations. The registry provides scientists and attending physicians with access to a huge sample of myeloma patient records.
This data allow us the assessment of adverse reactions in large patient populations outside clinical trials.
| Data (Nov. 2017) | N | Details |
| Austrian centers | 17 | AMR MAP |
| International centers | 3 | Port Elisabeth, Bari, Budapest |
| Medical records | 1361 | |
| PRO – time points | 624 |
History
The Austrian Myeloma Registry (AMR) is an initiative within the framework of health services research and quality control under the patronage of the Austrian Society of Hematology & Medical Oncology (OeGHO).
The development took place in 2008 within the COMET programs Oncotyrol I and II with additive funding through donations from the pharmaceutical industry and the non-profit Tyrolean Association for the Advancement of Cancer Research e.V.
The development took place in 2008 within the COMET programs Oncotyrol I and II with additive funding through donations from the pharmaceutical industry and the non-profit Tyrolean Association for the Advancement of Cancer Research e.V.
01.
Quality
The shift from acute cancer care to treating cancer as a chronic disease, quality assurance (QA) is becoming increasingly important in the medical treatment of cancer patients. Therefore, the registry provied valide longitudinal data from a large patient population under ‘real life’ conditions.
02.
Challenge
Increasing complexity of modern diagnostics and therapy, the international recognition and dissemination of evidence-based treatment guidelines and the increased interest of patients, doctors and socual insurance companies in the transparency of services and the results of medical care.
03.
Innovations
Linking Clinical Patient Data & Patient Reported Outcomes.
- Monitoring of patients at home to improve early detection of clinically important problems for personalized therapy guidance.
- Database withdetailed, naturalistic data on QoL and PROs for the longitudinal evaluation of specific hematologic treatment strategies.
- Analysis of comparative effectiveness of medical interventions including the patient’s perspective.
- Individualized feedback tool to inform patients about their current conditions and tips for improvement of subjective well-being for improved patient compliance and therapy outcome.
- Increased efficiency of hospital units.
04.
Safety
Secure, accessible, and efficient storage of data is paramount for the success of clinical trials specifically and the usage of software systems in daily clinical routine in general. In the context of systems recording their data electronically, this results in distinct requirements for securing the servers that are used for data collection.
Check Out Our Services!
SAVE THE DATE
10. November 2017 – 09:00 bis 17:30 Uhr
Malignant Pleural Mesothelioma: Advances in diagnostics, therapy & research
Ruhrlandklinik Essen
16. November 2017 – 18. November 2017
14. AIO-Herbstkongress
Berlin, Deutschland
28. September – 2. Oktober 2018
Jahrestagung 2018 der DGHO, OeGHO, SGMO und SGH
Wien, Österreich
MULTIMEDIA
UPCOMING FEATURES
- HL7 Interface to PRO’s
- DeAnonyimzer
- Individual, storeable export templates
- Generating reports
PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. Lancet. 2017 Oct 20. pii: S0140-6736(17)32134-7.
Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Steiner N, Borjan B, Hajek R, Jöhrer K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G. Oncotarget. 2017 Apr 21;8(34):56243-56254
Querschnittslähmung durch eine seltene Ursache: Differenzialdiagnose eines sekundären intramedullären Non-Hodgkin-Lymphoms. Mangesius S, Willenbacher W, Gizewski ER. Rofo. 2017 Oct;189(10):992-994. doi: 10.1055/s-0043-117886. Epub 2017 Sep 14
Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H. Genes Cancer. 2016 Sep;7(9-10):301-308.
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. Blood. 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22
Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H. Genes Cancer. 2016 Sep;7(9-10):301-308.
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. Blood. 2017 Jan 19;129(3):383-385.
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K. Oncotarget. 2016 Nov 29;7(48):78605-78618.
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M. Oncologist. 2016 Sep;21(9):1107-12.
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study. Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M. Ann Hematol. 2016 Jun;95(7):1107-14.
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14). Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R. Eur J Cancer. 2016 May;58:112-21.
LOOKING BACK ON 5 YEARS OF HORIZON SCANNING IN ONCOLOGY. Nachtnebel A, Breuer J, Willenbacher W, Bucsics A, Krippl P, Wild C. Int J Technol Assess Health Care. 2016 Jan;32(1-2):54-60.
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W; Austrian Myeloma Registry (AMR). PLoS One. 2016 Mar 3;11(3):e0147381.
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR). Willenbacher W, Thangavadivel S, Greil R, Willenbacher E, Weger R, Manzl C, Jöhrer K, Brunner A. Leuk Lymphoma. 2016 Oct;57(10):2330-41.
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Blood Cancer J. 2016 Jan 8;6:e378
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? Mondello P, Steiner N, Willenbacher W, Arrigo C, Cuzzocrea S, Pitini V, Mian M. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):82-8.
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma–an analysis from the Austrian Myeloma Registry. Willenbacher W, Willenbacher E, Zelle-Rieser C, Biedermann R, Weger R, Jöhrer K, Brunner A. Leuk Lymphoma. 2016;57(6):1478-81.
OUR TEAM
Highly qualified specialists
Roman Weger, M.Sc.
Registry-Coordinator & Project Manager Oncotyrol
Center for Personalized Cancer Medicine GmbH,
Karl-Kapferer-Straße 5
6020 Innsbruck/Austria
E-Mail: roman.weger@tirol-kliniken.at
ACMIT Austrian Center for
Medical Innovation and Technology
Viktor Kaplan-Straße 2/1, 2700 Wiener Neustadt
E-Mail: roman.weger@acmit.at
Wolfgang Willenbacher, M.D.,
Senior Medical Officer
Center for Personalized Cancer Medicine GmbH,
Karl-Kapferer-Straße 5
6020 Innsbruck/Austria
E-Mail: wolfgang.willenbacher@tirol-kliniken.at
CONTACT
Start a project with us!
Karl-Kapferer-Straße 5
6020 Innsbruck/Austria
6020 Innsbruck/Austria
Interested in joining the registry
If you would like to proceed further information regarding the International Myeloma Registry or need more informations regarding a DEMO access, feel free to leave us a message..
LOGIN
Login to the register or to the test system!
PARTNER
Partners and promotions
Celgene
Janssen-Cilag
Tirol Kliniken
Address: Anichstraße 35, A-6020 Innsbruck
Home: https://www.tirol-kliniken.at/
Phone: +43 0512 504 576523
Novartis
Address: Stella-Klein-Loew-Weg 17, A-1020 Wien
Home: https://www.novartis.at/
Phone: +43 01 866 57 0
ACMIT
Viktor Kaplanstraße 2/1 Building A
2700 Wiener Neustadt/ Austria
Home: www.acmit.at
Phone: +43 2622 22859 – 0
For questions concerning data protection please contact roman.weger@tirol-kliniken.at or phone +43 504 – 0